MGNX News and Press, MacroGenics Inc. From 05/10/24

2024-05-10 08:03:03 ET More on MacroGenics MacroGenics, Inc. (MGNX) Q1 2024 Earnings Call Transcript MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024 MacroGenics, Inc. (MGNX) Q4 2023 Earnings Call Transcript MacroGenics GAAP EP...

2024-05-10 06:15:06 ET BMO Capital analyst issues MARKET PERFORM recommendation for MGNX on May 10, 2024 04:23AM ET. The previous analyst recommendation was Outperform. MGNX was trading at $14.67 at issue of the analyst recommendation. The overall analyst consensus : BUY...

2024-05-10 06:00:03 ET Etzer Darout from BMO Capital issued a price target of $8.00 for MGNX on 2024-05-10 04:23:00. The adjusted price target was set to $8.00. At the time of the announcement, MGNX was trading at $14.67. The overall price target consensus is at $19.75 w...

2024-05-10 02:15:10 ET Image source: The Motley Fool. MacroGenics (NASDAQ: MGNX) Q1 2024 Earnings Call May 09, 2024 , 4:30 p.m. ET Operator Continue reading For further details see: MacroGenics (MGNX) Q1 2024 Earnings Call Transcript

2024-05-10 00:48:02 ET MacroGenics, Inc. (MGNX) Q1 2024 Earnings Conference Call May 9, 2024 16:30 ET Company Participants Jim Karrels - Senior Vice President and Chief Financial Officer Scott Koenig - President and Chief Executive Officer Conference Call Parti...

2024-05-09 17:47:18 ET Gainers: Inseego ( INSG ) +22% . Natera ( NTRA ) +18% . CareDx ( CDNA ) +13% . SoundHound  ( SOUN ) +13% . Funko ( FNKO ) +12% . Losers: MacroGenics ( MGNX ) -62% . Progyny ( PGNY...

2024-05-09 16:29:30 ET More on MacroGenics MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024 MacroGenics, Inc. (MGNX) Q4 2023 Earnings Call Transcript MacroGenics: Evaluating Its Buy Status After A 200% Surge On Prostate Cancer Prospect...

Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patients Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a bio...

ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial re...

2024-04-05 02:31:21 ET Summary Positive safety update released from phase 2 TAMARACK study, using vobra duo for the treatment of patients with metastatic castration-resistant prostate cancer. Updates to interim data from the phase 2 TAMARACK study expected by May 31st of 2024. ...